false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Didactics
KEYNOTE A18: Pembrolizumab versus placebo + chemo ...
KEYNOTE A18: Pembrolizumab versus placebo + chemo for locally advanced cervical cancer
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video provides an overview of a study evaluating Pembrolizumab combined with chemoradiotherapy for high-risk, locally advanced cervical cancer. Cervical cancer, particularly prevalent in Sub-Saharan Africa, Central America, and Southeast Asia, sees current treatments often failing. The study reported Pembrolizumab improving progression-free and overall survival, supported by strong global data from over 1,000 patients. Despite some limitations, the combination emerges as a viable treatment, transforming the standard of care alongside existing options like the Interlace protocol. However, treatment choice may depend on drug availability and resource constraints.
Asset Subtitle
Glenn Boyles
Feb 2025
Keywords
Pembrolizumab
cervical cancer
chemoradiotherapy
progression-free survival
global data
Contact
education@igcs.org
for assistance.
×